Ra Pharmaceuticals Inc (NASDAQ:RARX), Ocular Therapeutix Inc (NASDAQ:OCUL)

Ivan Schwartz
July 17, 2017

(NASDAQ:OCUL) during the first quarter, according to its most recent disclosure with the SEC. Similar statistics are true for the second largest owner, Versant Venture Management, Llc, which owns 2,215,384 shares of the stock are valued at $14.74 million. Ocular Therapeutix earned a media sentiment score of -0.06 on Accern's scale. Columbus Circle Investors boosted its position in shares of Ocular Therapeutix by 131.4% in the first quarter.

Analysts reviewing Ocular Therapeutix, Inc. have recently updated their recommended buy/sell ratings and price targets on the stock. Deltec Asset Management LLC now owns 399,200 shares of the biopharmaceutical company's stock valued at $3,705,000 after buying an additional 284,200 shares in the last quarter. State Street Corp now owns 238,921 shares of the biopharmaceutical company's stock worth $2,000,000 after buying an additional 42,761 shares during the period. JPMorgan Chase & Co. bought a new position in shares of Ocular Therapeutix during the first quarter valued at $3,394,000. Teachers Advisors LLC raised its stake in shares of Ocular Therapeutix by 47.7% in the fourth quarter. (NASDAQ:OCUL) opened at 6.33 on Friday. The firm exchanged a volume of 2.57 million shares at hands. The third largest holder is Sv Health Investors, Llc, which now holds $10.68 million worth of this stock and that ownership represents almost 5.42% of its market capitalization. Zooming out to the 200-day moving average, shares have been seen trading -22.00% away from that value. Morgan Stanley downgraded Ocular Therapeutix Inc (NASDAQ:OCUL) on Friday, October 23 to "Equal-Weight" rating. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.48) by $0.10.

3 analysts on average are expecting the company to report revenue of $550000 for the current quarter. The Return on Equity (ROE) value stands at -80.2%. During the same period in the previous year, the company posted ($0.35) earnings per share.

Returns and Valuations for Ocular Therapeutix, Inc.

Auburn linebacker Tre' Williams named to Butkus Award watch list
The award named after legendary linebacker Dick Butkus has been presented by the Butkus Foundation in every year since 1985. Vanderbilt from Tyler Ferguson was the longest of his career, and he added more fireworks in the return game.

Virat Kohli was reluctant against Virender Sehwag's proposal as Team India coach
Arun was India's bowling coach from 2014 to 2016 and formed a strong partnership with Shastri when he was the team director. However, the former Tamil Nadu pacer seems to be ready to take up the role and join Shastri's camp once again.

Amazon signals that it wants in the meal-kits business
Amazon's July 6 trademark application calls for the delivery of "prepared food kits. ready for cooking and assembly as a meal". TheStreet.com is reporting that Amazon filed a trademark application earlier this month for a rival meal-kit business.

COPYRIGHT VIOLATION NOTICE: "Wells Fargo & Company MN Boosts Position in Ocular Therapeutix, Inc". If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & global copyright and trademark legislation.

A number of other equities analysts also recently commented on OCUL.

Ocular Therapeutix, Inc. (OCUL) has a market capitalization of 183.75 Million which suggests the company is a huge company further suggesting that the shares of Ocular Therapeutix, Inc. BTIG Research reiterated a "buy" rating and set a $13.00 price objective on shares of Ocular Therapeutix in a research report on Tuesday, March 21st. The rating was maintained by Cantor Fitzgerald on Monday, July 10 with "Buy". Morgan Stanley lowered shares of Ocular Therapeutix from an "overweight" rating to an "equal weight" rating and set a $16.00 price objective for the company.in a research note on Friday, June 23rd. The stock of Ocular Therapeutix Inc (NASDAQ:OCUL) has "Overweight" rating given on Friday, February 10 by Cantor Fitzgerald. A 5 analysts rate it as either a buy or a strong buy, while 1 believe that investors should either steer clear of (NYSE:PEG) or, if they already own its stock, sell it. The stock closing price is now trading downward to its 50 day moving average with change of -32.26%, tumbled to its 20 day moving average with figure of -30.31% and behind its 200 day moving average with value -22.00%.

On May 5, 2017, Ocular Therapeutix disclosed that the U.S. Food and Drug Administration had found minor issues at its manufacturing plant.

Other reports by GizPress

Discuss This Article